Trial
NCT02606266
Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
—
Condition
Congenital Cytomegalovirus (CMV)
Intervention
Valganciclovir
Why stopped
No eligibles patients
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-11-18